858643-95-5

Basic information

• Product Name: Tert-butyl3-acetylpyrrolidine-1-carboxylate
• Synonyms: Tert-butyl3-acetylpyrrolidine-1-carboxylate;1-Boc-3-acetyl-pyrrolidine;3-Acetyl-1-Boc-pyrrolidine;N-Boc-3-acetyl-pyrrolidine;3-Acetyl-pyrrolidine-1-carboxylic acid tert-butyl ester
• CAS NO: 858643-95-5
• Molecular Formula: C11H19NO3
• Molecular Weight: 213.27346
• Mol File: 858643-95-5.mol

Chemical Properties

• Boiling Point: 293.83 °C at 760 mmHg
• Flash Point: 131.504 °C
• Appearance: /
• Density: 1.076 g/cm³
• Storage Temp.: 2-8°C
• Solubility: Chloroform, Ethyl Acetate
• PKA: -2.57±0.40(Predicted)
• CAS DataBase Reference: Tert-butyl3-acetylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-butyl3-acetylpyrrolidine-1-carboxylate(858643-95-5)
• EPA Substance Registry System: Tert-butyl3-acetylpyrrolidine-1-carboxylate(858643-95-5)

Safety Data

• Hazardous Substances Data: 858643-95-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Tert-butyl3-acetylpyrrolidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for selective functionalization and the formation of complex molecular architectures that are valuable in medicinal chemistry.
Used in Bioactive Molecule Development:
In the field of bioactive molecule development, Tert-butyl3-acetylpyrrolidine-1-carboxylate serves as a building block for creating novel compounds with potential biological activities. Its presence in a molecule can influence properties such as solubility, stability, and binding affinity to biological targets.
Used in Selective Inhibitors of H. influenzae TrmD:
Tert-butyl3-acetylpyrrolidine-1-carboxylate is used as a selective inhibitor of H. influenzae TrmD, a protein involved in tRNA modification. It functions by mimicking tRNA interaction, inducing the ordering of the TrmD lid domain, which is crucial for the enzyme's activity. This application is particularly relevant in the development of new antimicrobial agents targeting specific bacterial proteins.
Used in Organic Synthesis Research:
In the realm of organic synthesis research, Tert-butyl3-acetylpyrrolidine-1-carboxylate is employed as a model compound to study various synthetic methodologies and reaction mechanisms. Its reactivity and structural features make it an ideal candidate for exploring new routes to complex organic molecules.

Upstream product

• 569667-93-2 tert-butyl 3-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate 
• 75-16-1 methylmagnesium bromide 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 

Downstream Products

• 1225218-94-9 tert-butyl 3-(2-bromoacetyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl, or R1b and R1c together form an optionally substituted C3-C6 cycloalkyl ring, or R1d and R1e together form an optionally substituted C3-C6 cycloalkyl ring; R2 represents hydrogen or optionally substituted C1-C6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

Novel Compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

Selective inhibitors of bacterial t-RNA-(N1G37) methyltransferase (TrmD) that demonstrate novel ordering of the lid domain

The tRNA-(N1G37) methyltransferase (TrmD) is essential for growth and highly conserved in both Gram-positive and Gram-negative bacterial pathogens. Additionally, TrmD is very distinct from its human orthologue TRM5 and thus is a suitable target for the design of novel antibacterials. Screening of a collection of compound fragments using Haemophilus influenzae TrmD identified inhibitory, fused thieno-pyrimidones that were competitive with S-adenosylmethionine (SAM), the physiological methyl donor substrate. Guided by X-ray cocrystal structures, fragment 1 was elaborated into a nanomolar inhibitor of a broad range of Gram-negative TrmD isozymes. These compounds demonstrated no activity against representative human SAM utilizing enzymes, PRMT1 and SET7/9. This is the first report of selective, nanomolar inhibitors of TrmD with demonstrated ability to order the TrmD lid in the absence of tRNA.

N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES

This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preve

BIARYL CARBOXAMIDES

This invention provides compounds of Formula (I) which are PAFR antagonists: Formula (I) and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.

Microwave-assisted synthesis of novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamates

A straightforward approach to novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamate building blocks is presented in this study. Their construction is achieved by condensation of N-carbamate a- and β-amino carbonyl derivatives with l-methyl-3,5-dinitro-2-pyridone 1 under microwave irradiation. Judiciously chosen modifications in the nature of the parent carbonyl starting material has influenced the regiochemical outcome of the reaction and allowed an efficient access to novel nitrogen-containing scaffolds. Compounds sharing morphological similarities have been gathered in three libraries differing from each other in a single structural parameter.